

## CLINICAL EVALUATION AND CARDIOVASCULAR EFFECTS OF CARTEOLOL (ARTEOPTIC®) --- THE ROLE OF ISA

Mei-Ju Chen, Joe C.K. Chou

Jorn-Hon Liu

Carteolol(Arteoptic®) is the only one non-selective Beta-blocker with ISA(Intrinsic Sympathomimetic Activity) now. Thirteen POAG patients under 0.5% Timolol and thirteen NTG without treatment patients were enrolled in this study. All patients had complete eye examinations and systemic vital signs checkup before and after Carteolol use. IOP, SBP, DBP, PR, subjective symptoms were taken in the visits scheduled at 2,4,8,12 weeks with data recorded and analysed. After 12 weeks therapy, Carteolol reduced IOP approximately 7-19% in patients with NTG with statistically significance and achieved good

IOP control in patients with POAG. The reduction of SBP ranged between 4 and 11 mmHg and DBP between 2 and 8 mmHg while the PR reduction was less than 3 bpm. No statistically significant difference was found in the SBP, DBP and PR in both groups. Most patients reported no subjective symptoms except few gritty sensation and transient blurred vision. Beta-adrenergic antagonists with ISA have been shown to cause less systemic cardiovascular effects in literatures. Therefore, they may be useful in patients in whom old aged, bradycardia, poor cardiovascular function, or high risk NTG is a Problem.

智慧藏

---

Received: March 30, 1998, Revised: May 20, 1998, Accepted: December 18, 1998.

Department of Ophthalmology, Veterans General Hospital -Taipei, National Yang-Ming University Taipei  
Taiwan Republic of China.

Correspondence and reprint requests to: Mei-Ju Chen, Department of Ophthalmology, Veterans General Hospital,  
Taipei, 201, Sec. 2, Shih-Pai Rd., Taipei, Taiwan.